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Background: There is an HIV epidemic among people who inject drugs (PWID) in Manipur and Nagaland,
Northeast India. Approximately one-third of PWID across these two states are aged below 25 years, yet until now
there has been no systematic investigation of the differences between the younger and older PWID. We sought to
profile differences in drug use and sexual practices across age groups and to examine whether age is associated
with injecting and sexual risk behaviours.
Methods: We used combined cross-sectional survey data collected in 2009 from two surveys involving a total of
3,362 (male) PWID in eight districts of Manipur and Nagaland. All data were collected using interviewer-
administered questionnaires.
Results: Compared to PWID aged 35 years or older, PWID aged 18 to 24 years were more likely share needles/
syringes in both Manipur (OR =1.8) and Nagaland (OR =1.6). Compared to PWID aged 35 years or older, PWID aged
18 to 24 years were almost two times as likely to draw up drug solution from a common container at their last
injection in Manipur (OR =1.8). In Nagaland, PWID aged 18 to 24 years were more likely to use condoms
consistently with both casual (OR =3.1) and paid (OR =17.7) female sexual partners compared to PWID aged
35 years or older.
Conclusion: Risky injecting practices were more common among younger PWID in both Manipur and Nagaland,
while unprotected sex was more common among older PWID in Nagaland. There is a clear need to focus public
health messages across different age groups.
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People who inject drugs (PWID) are at high risk of
infection with blood-borne viruses and are targeted by
HIV prevention interventions around the world [1,2].
Approximately 10% of HIV infections worldwide are at-
tributable to injecting drug use, and several countries in
Asia are confronting serious HIV epidemics among PWID
[3]. In India, risky injecting practices remain common and
represent an important driver of new HIV infections* Correspondence: g.armstrong@unimelb.edu.au
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article, unless otherwise stated.[4-6]. Additionally, risky sexual behaviours are common
among PWID in India generating opportunities for the
transmission of HIV and sexually transmitted infections
(STIs) [4,5].
Manipur and Nagaland are two states in the northeast
region of India, an ethnically distinct and geographically
isolated part of the country that is characterized by
substantial under-development [7]. Both of these states
share a long porous border with Myanmar, one of the
world’s largest producers of heroin, and injecting of
opiates has been practiced since the mid-1980s [7,8].
Approximately 2% of the population inject drugs; the
most commonly injected drugs are heroin and Spasmo-
proxyvon (SP), the brand name for a synthetic opiatetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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hydrochloride and paracetamol [9].
Manipur and Nagaland are among the states with the
highest HIV prevalence in India [10], and unsafe inject-
ing drug use has made a major contribution to the HIV
epidemic in this region [11-14]. In 2009, adult HIV
prevalence was estimated to be 1.4% in Manipur and
0.8% in Nagaland (compared to 0.3% at the national
level) [15]. HIV prevalence among PWID (according to
2010–11 government sentinel surveillance) was esti-
mated to be 12.9% in Manipur and 2.2% in Nagaland
[10]. The HIV prevalence in Manipur is consistently
higher than Nagaland. This is in part due to very different
patterns of drug use in the two states. PWID in Manipur
mainly inject heroin, while those in Nagaland use SP (a
synthetic opioid containing dextropropoxyphene) [16]. SP
is very damaging to veins, so after a few years of use,
injecting is no longer possible. As SP can be taken orally,
the person does not always have to inject, so less injecting
takes place overall.
The response to HIV and injecting drug use in Manipur
and Nagaland was historically punitive but is now
guided by internationally recognized harm reduction
principles [7]. The HIV prevention response is coordi-
nated by the government through the National AIDS
Control Organization (NACO) and the respective State
AIDS Control Societies (SACS). Alongside this, Avahan
(Bill & Melinda Gates Foundation in India) funded Project
ORCHID to coordinate a range of local non-government
organizations (NGOs) to implement HIV prevention in-
terventions in selected districts of Manipur and Nagaland
over a 10-year period (2004–14). Regardless of funding
source, most of the targeted HIV prevention interventions
in Manipur and Nagaland are delivered in the field by
local NGOs. To evaluate the HIV prevention interven-
tions, and to better understand the dynamics of the HIV
epidemic, two surveys were conducted in separate districts
of Manipur and Nagaland in 2009: the Integrated Behav-
ioural and Biological Assessment (IBBA) [17] and the Be-
havioural Tracking Survey (BTS) [16].
Elsewhere in the world, research has highlighted im-
portant differences between younger and older PWID
[18], including a greater propensity to engage in risky
injecting practices among younger injectors [19-23], sug-
gesting that they are an important target group for harm
reduction interventions. A high proportion of PWID in
Manipur and Nagaland (i.e., >40% in most districts) are
aged below 25 years [16], yet until now there has been
no systematic investigation of the differences in injecting
practices and sexual behaviours between the younger
and older PWID in these states. This paper reports on
analyses of IBBA and BTS data, and the objectives are 1)
to profile differences in demographics, drug use and
sexual practices across age groups and 2) to examinewhether age is correlated with injecting and sexual risk
behaviours. The findings from our analyses have implica-
tions for HIV prevention programmes working with
PWID in these two states.
Methods
Study design
Data for this study was obtained from two separate
cross-sectional surveys: the IBBA conducted in two districts
of Manipur (Churachandpur, Bishnupur) and Nagaland
(Wokha, Phek) and the BTS also conducted in two districts
of Manipur (Chandel, Ukhrul) and Nagaland (Kiphere,
Zunheboto). The HIV prevention programme in all
eight districts was auspiced by the Bill & Melinda Gates
Foundation—funded Project ORCHID. Both surveys
collected information from men who inject drugs during
2009 using an interviewer-administered questionnaire and
the same sampling approach (discussed below). As the
BTS questionnaire was adapted from the IBBA question-
naire, many of the questions were the same, so it was
feasible to combine data pertaining to variables common
to both databases, incorporating all eight districts. The
methods for both the IBBA and the BTS have been de-
scribed in depth elsewhere [16,17,24,25] and are summa-
rized below.
Ethical approval for the IBBA was obtained in India
through the Ethical Review Boards of the participating in-
stitutions: FHI360, the Regional Medical Research Centre
(RMRC) in Dibrugarh, and the National AIDS Research In-
stitute (NARI). Ethical approval for the BTS was obtained
from the Institutional Review Board of the Emmanuel
Hospital Association (EHA), New Delhi. Informed consent
was obtained from all participants prior to administration
of the behavioural questionnaire and biological testing, and
confidentiality was assured.
Sampling and participants
Respondent-driven sampling (RDS) was used to recruit
participants for both the IBBA and BTS. RDS is a
probability-based method for sampling from hidden popu-
lations that recruits participants using peer networks [26].
To be eligible to participate in the study, participants
needed to be males aged 18 years or older and to have
injected drugs for non-medical purposes at least once
during the last 6 months. Peer educators with good
knowledge of the local injecting drug use context were
employed to screen potential participants and ensure
they met the eligibility criteria.
Data collection
Interviewer-administered questionnaires were used to
collect data on demographics, drug use history and prac-
tices, sexual behaviours and participation in HIV testing.
Only the IBBA participants provided blood and urine
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were tested for HIV, hepatitis C (HCV) and syphilis anti-
bodies, and urine samples were tested for Chlamydia
trachomatis (CT). Serum samples were tested for HIV
by Microelisa (J.Mitra and Company, New Delhi, DL,
India), and positive tests were confirmed by Genedia HIV
1/2 ELISA 3.0 (Green Cross Life Science Corporation,
Yongin, South Korea). Serum samples were tested for
syphilis by rapid plasma reagin (RPR) test and confirmed
by Treponema pallidum haemagglutination assay (TPHA).
Serum samples were also tested for HCV antibody by EIA
(Murex anti-HCV Version 4.0, Abbott Diagnostics, North
Chicago, IL, USA). Urine samples were tested with nucleic
acid amplification assay (Gen-Probe Aptima, San Diego,
CA, USA) for the detection of CT.
Sample size
For both the IBBA and BTS, a sample size of 400 in each
district was estimated based on an ability to detect
changes in proportions of 15% at follow-up surveys from
estimated baseline values of 50% (which yield the biggest
sample size), an alpha level of 0.05, a power of 90%, and
a design effect of 1.5.
For the IBBA, a total of 1,650 participants (PWID) were
recruited: 410 from Bishnupur, 411 from Churachandpur,
418 from Phek, and 411 from Wokha. For the BTS, a total
of 1,712 participants (PWID) were recruited: 421 from
Ukhrul, 415 from Chandel, 427 from Kiphire and 449
from Zunheboto. By combining the two samples, we
achieved a total sample size of 3,362, which is 1% of the
estimated combined total PWID population for Manipur
(12,592) and Nagaland (19,959) [10,27].
Statistical analysis
Descriptive data obtained using RDS is typically analysed
using special statistical software packages to account for
the complex sampling design such as RDSAT [28,29].
Our analyses are based on data combined from RDS sur-
veys conducted in eight districts across Manipur and
Nagaland, and it would not be legitimate to treat the
data as one large RDS study because the RDS data col-
lection coding systems were unique to each district. As
such, all analyses were performed using SPSS version 21
without adjustment for the complex sampling design.
Consequently, it is important to note that the results of
these analyses should be viewed as if the sample were a
large convenience one. The Chi-square test was used to
examine differences in participant characteristics across
three age groups (18–24 years, 25–34 years and 35 years
or older). Binary logistic regression analyses using the
forced entry method were conducted to examine whether
age is correlated with unsafe injecting practices (i.e. nee-
dle/syringe sharing and drawing up drugs from common
containers) and condom use with regular, casual and paidpartners. Models examining the association of age with
unsafe injecting behaviour were adjusted for key demo-
graphics (i.e. literacy, marital status), key drug use prac-
tices (i.e. length of injecting career, frequency of injecting,
most commonly injected drug) and exposure to needle
syringe programmes that disseminate HIV prevention in-
formation (i.e. usual place of procuring needles/syringes);
models examining the association of age with condom use
were additionally adjusted for the number of sexual part-
ners in the past year. For all logistic regression analyses,
both unadjusted and adjusted odds ratios are presented
along with their respective 95% confidence intervals. Only
models with acceptable diagnostics are presented; good-
ness of fit was assessed using the Hosmer Lemeshow test,
and collinearity was assessed using the variance inflation
factor (VIF). The results from the two states are reported
separately because they are very different from each other
both in relation to drug use patterns and HIV prevalence.Results
By combining the data from the IBBA and the BTS, we
accumulated a sample of 1,657 PWID in Manipur and
1,705 PWID in Nagaland. In Manipur, 23.7% (n =392)
were aged 18 to 24 years, 54.1% (n =897) were aged 25
to 34 years, and 22.2% (n =368) were aged 35 and over.
In Nagaland, the participants were substantially younger;
43.6% (n =743) were aged 18 to 24 years, 45.9% (n =783)
were aged 25 to 34 years, and just 10.5% (n =179) were
aged 35 and over. The median age at first injection was
22.0 years in both Manipur and in Nagaland; the pro-
portion of participants who first injected before the age
of 20 years was 26.9% (n =444) in Manipur and 26.2%
(n =443) in Nagaland.Demographics, drug use and sexual practices across age
groups
Differences in demographics, drug use and sexual prac-
tices across age groups are profiled in Table 1. Higher
proportions of younger PWID were literate and had
never been married. Older PWID were more likely to
have been injecting for a longer period (i.e. 3 or more
years); however, a substantial proportion of PWID aged
18 to 24 years had been injecting for 3 years or more in
both Manipur (35.6%) and Nagaland (28.4%). In Nagaland,
younger PWID aged 18 to 24 years (65.3%) were more
likely to usually obtain their new needles/syringes from
NGO-delivered needle syringe programmes (NSPs) com-
pared to PWID aged 35 years or older (40.3%). In
Manipur, drawing up drugs from a common container
was more prevalent behaviour in younger PWID aged 18
to 24 years (27.3%) compared to PWID aged 35 years or
older (17.7%); however, there were no differences across
age groups in either state regarding the proportion of
Table 1 Participant characteristics across age groups, by state













Total % (n) p valuea
Literacy 0.017 0.013
Illiterate 9.4 (37) 7.5 (67) 12.5 (46) 9.1 (150) 18.3 (136) 23.8 (186) 25.7 (46) 21.6 (368)
Literate 90.6 (355) 92.5 (830) 87.5 (322) 90.9 (1,507) 81.7 (607) 76.2 (597) 74.3 (133) 78.4 (1,337)
Marital status <0.001 <0.001
Never married 89.5 (351) 53.6 (481) 18.8 (69) 54.4 (901) 91.9 (683) 52.9 (413) 17.4 (31) 66.2 (1,127)
Currently married 8.2 (32) 36.6 (328) 66.6 (245) 36.5 (605) 6.9 (51) 42.6 (333) 73.0 (130) 30.2 (514)
Widowed/divorced/separated 2.3 (9) 9.8 (88) 14.7 (54) 9.1 (151) 1.2 (9) 4.5 (35) 9.6 (17) 3.6 (61)
Length of injecting career <0.001 <0.001
< 3 years 64.4 (251) 20.8 (186) 13.7 (50) 29.5 (487) 71.6 (530) 33.6 (262) 21.7 (38) 49.0 (830)
≥ 3 years 35.6 (139) 79.2 (708) 86.3 (316) 70.5 (1,163) 28.4 (210) 66.4 (517) 78.3 (137) 51.0 (864)
Most commonly injected drug <0.001 0.004
Heroin 87.8 (344) 96.8 (868) 99.5 (366) 95.2 (1,578) 14.9 (111) 18.8 (147) 8.4 (15) 16.0 (273)
SPb 6.9 (27) 2.2 (20) 0.3 (1) 2.9 (48) 82.1 (610) 77.7 (608) 86.0 (154) 80.5 (1,372)
Other 5.4 (21) 1.0 (9) 0.3 (1) 1.9 (31) 3.0 (22) 3.6 (28) 5.6 (10) 3.5 (60)
Frequency of injecting 0.140 0.244
Injected less than daily 35.1 (133) 33.0 (291) 28.5 (101) 32.5 (525) 79.9 (504) 76.1(537) 78.2 (133) 77.9 (1,174)
Injected daily 64.9 (246) 67.0 (590) 71.5 (254) 67.5 (1,090) 20.1 (127) 23.9 (169) 21.8 (37) 22.1 (333)
Place usually procure needles/syringes 0.391 <0.001
Needle syringe programme 77.3 (303) 79.5 (713) 82.9 (305) 79.7 (1,321) 65.3 (483) 51.4 (402) 40.3 (71) 56.3 (956)
Chemist / pharmacy 19.4 (76) 17.8 (160) 15.2 (56) 17.6 (292) 32.6 (241) 47.6 (372) 58.5 (103) 42.2 (716)
Other 3.3 (13) 2.7 (24) 1.9 (7) 2.7 (44) 2.2 (16) 1.0 (8) 1.1 (2) 1.5 (26)
Shared needle/syringe - past month 0.474 0.918
No 85.2 (310) 87.3 (748) 88.1 (310) 87.0 (1,368) 62.0 (426) 62.2 (423) 60.4 (90) 61.9 (939)
Yes 14.8 (54) 12.7 (109) 11.9 (42) 13.0 (205) 38.0 (261) 37.8 (257) 39.6 (59) 38.1 (577)
Drew drugs from common container
at last injection
0.005 0.786
No 72.7 (285) 75.5 (677) 82.3 (303) 76.3 (1,265) 48.9 (363) 50.6 (396) 50.3 (90) 49.8 (849)
Yes 27.3 (107) 24.5 (220) 17.7 (65) 23.7 (392) 51.0 (379) 49.4 (387) 49.7 (89) 50.1 (855)
Ever had sex <0.001 <0.001
No 25.8 (101) 9.6 (86) 4.9 (18) 12.4 (205) 14.8 (110) 3.3 (26) 0.0 (0) 8.0 (136)



















Table 1 Participant characteristics across age groups, by state (Continued)
Number of female sex partners -
past yearc
<0.001 <0.001
None 17.5 (51) 22.4 (182) 19.4 (68) 20.7 (301) 3.4 (21) 8.3 (62) 16.7 (29) 7.3 (112)
1 32.3 (94) 51.8 (420) 69.7 (244) 52.2 (758) 30.0 (186) 42.3 (315) 50.0 (87) 38.2 (588)
≥ 2 Partners 50.2 (146) 25.8 (209) 10.9 (38) 27.1 (393) 66.6 (413) 49.3 (367) 33.3 (58) 54.5 (838)
Female sexual partners – past yearc
Regular non-paid partner(s) 44.3 (129) 56.8 (461) 72.6 (254) 58.1 (844) <0.001 75.1 (471) 78.2 (589) 82.7 (148) 77.5 (1,208) 0.081
Casual non-paid partner(s) 47.8 (139) 21.8 (177) 9.1 (32) 24.0 (348) <0.001 55.1 (343) 39.1 (292) 27.5 (49) 44.2 (684) <0.001
Paid partner(s) 17.9 (52) 14.8 (120) 6.3 (22) 13.4 (194) <0.001 5.6 (35) 5.2 (39) 8.9 (16) 5.8 (90) 0.149
Consistent condom use with different
types of female partners – past yeard
Regular non-paid partner(s) 16.7 (21) 7.0 (32) 9.9 (25) 9.4 (78) 0.004 17.7 (82) 9.1 (53) 2.7 (4) 11.7 (139) <0.001
Casual non-paid partner(s) 28.4 (40) 16.6 (30) 17.6 (6) 21.3(76) 0.032 38.7 (135) 27.8 (83) 16.0 (8) 32.4 (226) <0.001
Paid partner(s) 57.7 (30) 43.3 (52) 50.0 (11) 47.9 (93) 0.219 52.8 (19) 34.1 (14) 18.8 (3) 38.7 (36) 0.049
Ever had an HIV test 31.6 (124) 58.7 (525) 62.0 (228) 53.0 (877) 0.000 37.2 (269) 46.3 (342) 43.8 (70) 42.0 (681) 0.002
Tested positive for different types
of infectionse
HIV 5.9 (9) 27.3 (138) 65.0 (106) 30.8 (253) 0.000 0.0 (0) 2.3 (9) 2.7 (3) 1.4 (12) 0.021
Hepatitis C (HCV) 53.3 (81) 74.9 (379) 90.2 (147) 73.9 (607) 0.000 8.8 (28) 16.4 (65) 21.4 (24) 14.1 (117) 0.001
Reactive syphilis serology 2.0 (3) 4.3 (22) 4.3 (7) 3.9 (32) 0.398 7.5 (24) 16.1 (64) 20.5 (23) 13.4 (111) <0.001
Chlamydia 2.6 (4) 2.0 (10) 0.6 (1) 1.8 (15) 0.384 12.5 (40) 7.6 (30) 4.5 (5) 9.1 (75) 0.014
ap value based on chi-square test.
bSpasmoproxyvon (SP), the brand name for a synthetic opiate analgesic containing dextropropoxyphene, dicyclomine hydrochloride and paracetamol.
cAmong sexually active participants.
dReported that, in general, condoms are used every time with this type of partner. Analysis based on sub-sample of participants who reported having these types of partners in the preceding 12 months.
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month.
In both states, a substantially higher proportion of
PWID aged 18 to 24 years had two or more female sexual
partners in the preceding 12 months (Manipur 50.2%,
Nagaland 66.6%) compared to PWID aged 35 or older
(Manipur 10.9%, Nagaland 33.3%). PWID of all ages re-
ported low levels of consistent condom use with the dif-
ferent types of female sexual partners; however, consistent
condom use with regular and casual partners was lowest
among older PWID.
Disease prevalence across age groups
Exposure to HIV testing was highest among older PWID.
Not surprisingly, PWID aged 35 years or older had a
much higher prevalence of HIV and HCV (Manipur, HIV
65.0%, HCV 90.2%; Nagaland, HIV 2.7%, HCV 21.4%)
compared to PWID aged 18 to 24 years (Manipur, HIV
5.9%, HCV 53.3%; Nagaland, HIV 0.0%, HCV 8.8%). In
Nagaland, the prevalence of reactive syphilis serology was
highest among older PWID and the prevalence of chla-
mydia was highest among younger PWID; there were no
significant differences in the prevalence of syphilis or chla-
mydia across age groups in Manipur.
Association between age and needle/syringe sharing
After adjusting for confounding, the likelihood of needle/
syringe sharing and drawing up drugs from a common
container was highest for PWID aged 18 to 24 years in
both states (Table 2). Compared to PWID aged 35 years
or older, PWID aged 18 to 24 years were over one and a
half times more likely to share needles/syringes in Manipur
(OR =1.84) and Nagaland (OR =1.60). Compared to PWID
aged 35 years or older, PWID aged 18 to 24 years were
almost two times as likely to have drawn up drug solu-
tion from a common container at their last injection in
Manipur (OR =1.79).
Association between age and condom use
The binary logistic regression model for consistent con-
dom use with different partners is presented in Table 3.
In Nagaland, PWID aged 18 to 24 years were more likely
to use condoms consistently with both casual (OR =3.12)
and paid (OR =17.65) female sexual partners compared to
PWID aged 35 years or older. In Manipur, there were no
statistically significant differences in the likelihood of con-
sistently using condoms with any partner between PWID
aged 18 to 24 and those aged 35 years or older.
Discussion
An important aspect of the demographic profile of PWID
in Manipur and Nagaland presented in this paper is that a
substantial proportion of the adult PWID participants
were aged 18 to 24 years in both states (Manipur =23.7%,Nagaland = 43.6%). Furthermore, in both Manipur and
Nagaland, one in four PWID first injected illicit drugs be-
fore the age of 20 years, indicating that many are entering
into injecting drug use at a young age. The analyses pre-
sented in this paper provide a greater understanding of
the differences between younger and older PWID so that
HIV prevention programmes can be targeted accordingly.
Risky injecting and sexual behaviours were common
among PWID in Manipur and Nagaland, coupled with a
high prevalence of HIV, hepatitis C and STIs. Interest-
ingly, our multivariate analyses reveal important and
somewhat conflicting differences between PWID across
age groups with regard to risky injecting practices and
sexual behaviours. After adjusting for a range of import-
ant confounders, younger PWID in both Manipur and
Nagaland were more likely to share needles/syringes,
and younger PWID in Manipur were also more likely to
draw up drug solutions from common containers, creat-
ing opportunities for HIV and HCV transmission. Yet by
contrast, younger PWID in Nagaland were more likely
to consistently use condoms with both casual and paid
female partners than older PWID.
Our finding that younger PWID are more likely to en-
gage in risky injecting behaviours has also been observed
in Delhi [30] and is not unique to this region of the
world. A high level of risky injecting behaviours has been
observed among younger injectors in Australia, Brazil,
Afghanistan and the United States [19-21,23]. A recently
published survey of almost 7,000 PWID across several
major cities in Australia found that after adjusting for
length of injecting career, each 5-year increase in age was
associated with an average 16% reduction in the likelihood
of receptive needle sharing [20]. One plausible explanation
for such results is that younger PWID have poorer know-
ledge of safe injecting practices and/or have less access to
clean injecting equipment. Another explanation is that
young adulthood is thought to be a time of experimenta-
tion and greater risk-taking and that young adults are
more vulnerable to peer influences that encourage risky
behaviour [31,32].
The local socio-cultural and political context for young
men in Manipur and Nagaland, a region with a rich tribal
history, is also relevant to understanding the behaviours of
younger PWID. Masculinity in the northeast is influenced
by a convergence of the traditional/tribal male warrior role,
with ethno-nationalism and armed struggle against the In-
dian state and between different ethnic and tribal groups
[33]. Research on initiation into injecting drug use among
PWID in Manipur and Nagaland found that injecting
among young men was closely connected with the influ-
ence of peers and social networking, as well as notions of
masculinity and a right of passage that bonds young men
with their friends [34,35]. If we adopt a youth and equity
lens [36,37], HIV prevention interventions in Manipur and
Table 2 Binary logistic regression for injecting risk behaviours across age groups, by state
Age (years) Manipur Nagaland
Sharing needles/syringes in past month Drew up drugs from common
container at last injection
Sharing needles/syringes in past month Drew up drugs from common
container at last injection
Unadjusted OR
(95% CI) (n =1,558)
Adjusted ORa
(95% CI) (n =1,537)
Unadjusted OR
(95% CI) (n =1,657)
Adjusted ORa
(95% CI) (n =1,608)
Unadjusted OR
(95% CI) (n =1,577)
Adjusted ORa
(95% CI) (n =1,362)
Unadjusted OR
(95% CI) (n =1,704)
Adjusted ORa
(95% CI) (n =1,487)
18–24 1.20 (0.78–1.82) 1.84 (1.10–3.08)* 1.75 (1.24–2.48)** 1.79 (1.17–2.73)** 0.89 (0.63–1.28) 1.60 (1.01–2.53)* 1.06 (0.76–1.46) 1.49 (0.98–2.26)
25–34 1.05 (0.73–1.51) 1.12 (0.76–1.65) 1.52 (1.11–2.06)** 1.35 (0.97–1.87) 0.94 (0.66–1.33) 0.98 (0.65–1.48) 0.94 (0.71–1.37) 1.33 (0.74–1.53)
35+ 1 1 1 1 1 1 1 1
*p <0.05; **p <0.01; ***p <0.001.























































































































35+ 1 1 1 1 1 1 1 1 1 1 1 1
*p <0.05; **p <0.01; ***p <0.001.
aReported that, in general, condoms are used every time with this type of partner; the other options (most of the times, sometimes, and never) were combined to construct a binary variable. Only participants with
these types of sexual partners over the past year were included in the analyses.
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people, such that: 1) young people have access to resources
(i.e. information and equipment such as needles/syringes),
2) drug services are “youth-friendly”, i.e. they engage with
and respond to the information and treatment needs of
young people, 3) information and education on drug use is
widely available to adolescents and 4) opportunities to
interrupt the transition to injecting drug use (e.g. life skills
programmes) are explored.
Our finding that younger PWID in Nagaland were sig-
nificantly more likely to consistently use condoms with
casual and paid female partners is a striking reversal of
the association between age and injecting risks. A study
among men attending sexually transmitted disease clinics
in Pune, India, similarly found that younger men were
more likely to use condoms than older men [38]. The au-
thors hypothesized that younger men have been exposed
to broader community HIV/STI awareness programmes
that promoted condom use, whereas older men were un-
likely to have benefitted from these education efforts. This
is probably true in the socially conservative context of
Northeast India as well, where it is only over the last dec-
ade or so that HIV/STI awareness programmes have
begun to widely promote the use of condoms. Further-
more, research conducted among men in Chennai, South
India, found that there was a need to develop a “condom
habit” from a young age, as using condoms at first sexual
experience was a strong predictor of future condom use
[39]. A different set of public health strategies may be
needed in order to reach older men with safe sex mes-
sages, particularly older PWID, many of whom may have
ingrained attitudes and behaviours regarding condom use.
Limitations
Our findings are subject to some limitations. Reporting
of certain behaviours may have been influenced by recall
and social desirability bias resulting in some risk behav-
iours being under-reported. As with all cross-sectional
surveys, causal relationships cannot be firmly determined.
All IBBA and BTS survey participants were recruited
using RDS and such data are typically analysed using
RDSAT to account for the complex sampling design. We
have combined data collected across eight districts for the
IBBA and BTS surveys to construct a large convenience
sample (n = 3,362) and have consequently been unable to
account for the complex sampling design in our analyses.
The limitation of our approach is that our analyses are es-
sentially based on a convenience sample with restricted
generalisability of the observed associations. Finally, the
participants were sampled through peer networks for the
IBBA and BTS surveys, and it is unknown how deep this
approach penetrated the sub-population of PWID in these
districts; it is possible that PWID who were not recruited
had different characteristics to the study participants.Conclusion
The analyses presented in this paper highlight important
differences in needle/syringe sharing and condom use
across age groups among PWID in Manipur and Nagaland,
Northeast India. Younger PWID were more likely to share
needles and syringes, and older PWID in Nagaland were
less likely to consistently use condoms with casual and paid
female partners. There is a clear need to promote different
harm reduction strategies across age groups to ensure that
younger PWID are more effectively reached with safe
injecting messages and equipment and safe sex messages
and condoms are effectively delivered to older PWID.
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